Arisan Therapeutics (co-PIs Michael Plewe and Ken McCormack) received a two year Advanced Technology Phase I SBIR award (R43AI12097)  in the first quarter of 2014.  

Entitled “Optimization of Arenavirus Antivirals”, the grant is for $600,000 from the National Institute of Allergy and Infectious Diseases.

The proceeds will be used for phase I medicinal chemistry optimization of a lead chemical series for the development of broad spectrum arenavirus antivirals through determination of activity in a variety of BSL2 pseudotype and live virus studies with final confirmation in BSL4 infectious Lassa virus in vitro studies.

This program resulted from a collaboration with scientists at the Scripps Research Institute.